MDM2 and prostate carcinoma: In this study, we found that inhibiting MDM2, either by siRNA or a pharmacological inhibitor of its RING domain, increased levels of AR, AR-V7, and TM4SF3 protein in prostate cancer cells, leading to elevated growth of these cells.